WAINZUA, Injektionslösung

7680693320017 CH-69332 Injektionslösung
WAINZUA, Injektionslösung
WAINZUA, Injektionslösung
WAINZUA, Injektionslösung
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Einzeldose(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
29/05/2025
Patient information leaflet
Français
29/05/2025
Patient information leaflet
Italien
29/05/2025
Summary of Product Characteristics
Allemand
29/05/2025
Summary of Product Characteristics
Français
29/05/2025
Summary of Product Characteristics
Italien
29/05/2025

Detailed composition

Substance Quantity Type Category
SOLU
56.0 MGML Substance Wirkstoff (Principe actif)
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HNIDK
SOLU
- Substance HBESI

Reimbursement information

Public price
CHF 31809.20
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/07/2025

Authorization holder

AstraZeneca AG

6340 Baar

Authorization information

Swissmedic authorization number
69332
Drug name
WAINZUA, Injektionslösung
Galenic form
INLFP
ATC Code
N07XX21
Authorization status
Z
Dispensing category
B
First authorization
14/02/2025
Authorization expiration date
13/02/2030
IT Number
01.99.0.
Domain
Human medicine
Field of application
Wainzua wird angewendet zur Behandlung erwachsener Patienten mit Polyneuropathie im Stadium 1 und 2 im Zusammenhang mit hereditärer Transthyretin-vermittelter Amyloidose (ATTRv).

Package details

Description (FR)
WAINZUA sol inj 45 mg/0.8ml stylo pré 0.8 ml
Description (DE)
WAINZUA Inj Lös 45 mg/0.8ml Fertpen 0.8 ml
Market launch
14/02/2025
Narcotic (BTM)
No

Application methods

SUBC